Novimmune SA has signed an international research collaboration with Baxalta to develop novel bispecific antibodies for an undisclosed indication. Financial terms were not disclosed.   The collaboration will use Novimmune’s new kappa-lambda bispecific antibody technology, a platform that generates fully human antibodies that target two specific binding sites with one antibody.   “The kappa-lambda platform is exactly the right technology for therapy areas which need a bispecific a...